BridgeMD
Tests treatment safety and results for Advanced Solid Tumors
Official title Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06384352
What this study is testing
What is YL211?
YL211 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for advanced solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.
- Aged ≥18 years.
- Be able and willing to comply with protocol visits and procedures.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or
- Adequate organ and bone marrow function. For Part 1: History of an advanced solid tumors (including locally advanced unresectable or metastatic...
You likely can't join if
- Prior treatment with an agent targeting c-MET (including antibody, ADC, chimeric antigen receptor T cell [CAR-T], and other drugs) with the exception...
- Previously received an ADC consisting of a TopoI
- Received continuous systemic steroids therapy for more than 28 days or require long-term (≥ 28 days) use of systemic steroids therapy within 28 days...
- A history of leptomeningeal carcinomatosis or carcinomatous meningitis
- Brain metastasis, except for the following situations: Participants with asymptomatic brain metastasis who do not require immediate local or systemic...
- Clinically significant concomitant pulmonary disease, including but not limited to: A history of drug-induced pneumonitis A history of...
The study team makes the final eligibility decision.
Where it's taking place
- Aurora, Colorado, United States
- Denver, Colorado, United States
- North Haven, Connecticut, United States
- Orlando, Florida, United States
- Sarasota, Florida, United States
- Las Vegas, Nevada, United States
- Cincinnati, Ohio, United States
- Houston, Texas, United States
- Irving, Texas, United States
- San Antonio, Texas, United States
- Gosford, New South Wales, Australia
- Nedlands, Western Australia, Australia
- Melbourne, Australia
- Toronto, Toronto, Canada
- Ottawa, Canada
- Beijing, Beijing Municipality, China
- Hangzhou, Zhejiang, China
- Wenzhou, Zhejiang, China
- Chengdu, China
- Guangzhou, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aurora, Colorado, United States; Denver, Colorado, United States; North Haven, Connecticut, United States; Orlando, Florida, United States; Sarasota, Florida, United States; Las Vegas, Nevada, United States and 14 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.